Ignota Labs Acquires Kronos`s Clinical Pipeline
06 Oct 2025 //
BUSINESSWIRE
Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
22 Aug 2022 //
GLOBENEWSWIRE
Kronos Bio`s SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022
12 May 2022 //
GLOBENEWSWIRE